Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study

Open access
Zatelli, Maria Chiara, Torta, Mirella, Leon, Antonette, Ambrosio, Maria Rosaria, Gion, Massimo, Tomassetti, Paola, De Braud, Filippo, Delle Fave, Gianfranco, Dogliotti, Luigi, Uberti, Ettore C degli, _, _·2007·Endocrine-Related Cancer

Abstract

Elevated circulating chromogranin A (CgA) levels are found in neuroendocrine tumors (NETs), but the diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the diagnosis of gastroenteropancreatic (GEP) NETs and the identification of metastatic patients, an Italian multicenter observational study has been performed. CgA was evaluated in 202 GEP NET patients by IRMA and ELISA. The cutoffs for diagnosis and presence of metastases were identified by receiver-operating characteristic (ROC) curve. We found good correlation between IRMA and ELISA. The ROC analysis identified a cutoff of 53 ng/ml for IRMA and 16 U/l for ELISA as discriminating between controls and patients with active disease (sensitivity 71.3 and 84%; specificity 71 and 85% respectively). Metastases were present in 123 patients, having significantly higher CgA levels than patients without metastases. ROC analysis identified a cutoff of 146 ng/ml for IRMA and 67.3 U/l for ELISA as discriminating between patients with and without metastases (sensitivity 57 and 63.3%; specificity 55.6 and 71.4% respectively). For pancreatic NETs positive and negative predictive values were 84 and 78% respectively (90% specificity and 68% sensitivity). We found lower CgA levels in patients with extensive metastatic spread than in those with liver metastases only. These data assess the role of CgA evaluation in GEP NETs, and demonstrate that higher CgA levels associate with metastatic disease, confirming that CgA levels can provide a helpful practical biochemical marker for the clinical management of NETs, but with low sensitivity and specificity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1677/erc-07-0001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 159

Metadata

Authors
Zatelli, M. C., Torta, M., Leon, A., Ambrosio, M. R., Gion, M., Tomassetti, P., De Braud, F., Delle Fave, G., Dogliotti, L., Uberti, E. C. D., & _, _.
Venue
Endocrine-Related Cancer
Published
2007-06
Volume
14
Issue
2
Pages
473-482
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2154295888
Cited by
159
References
1
FWCI
6.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. https://app.cochat.ai/papers/10.1677/erc-07-0001
The paper
Zatelli, M. C., Torta, M., Leon, A., Ambrosio, M. R., Gion, M., Tomassetti, P., De Braud, F., Delle Fave, G., Dogliotti, L., Uberti, E. C. D., & _, _. (2007). Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocrine-Related Cancer. https://doi.org/10.1677/erc-07-0001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.